<DOC>
	<DOCNO>NCT01353859</DOCNO>
	<brief_summary>This multicenter , open-label , single arm study assess safety efficacy RoActemra/Actemra ( tocilizumab ) combination methotrexate patient active rheumatoid arthritis inadequate response non-biologic disease-modifying antirheumatic drug ( DMARDs ) . Patients receive RoActemra/Actemra 8 mg/kg intravenously every 4 week total 6 infusion plus methotrexate 10-25 mg orally weekly . Anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Combination With Methotrexate Patients With Active Rheumatoid Arthritis Who Have Inadequate Response Non-biologic DMARDs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe active rheumatoid arthritis ( RA ) &gt; /= 6 month duration Prior treatment DMARDs &gt; /= 12 week ( stable dose &gt; /= 8 week ) Inadequate clinical response stable dose nonbiologic DMARD ( either single combination ) Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow enrollment Autoimmune disease RA History current inflammatory joint disease RA Previous treatment biologic drug use treatment RA Intraarticular parenteral corticosteroid within 6 week prior baseline Impaired liver , renal hematologic function Active current history recurrent infection History currently active primary secondary immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>